NovaBay Pharmaceuticals I... (NBY)
NovaBay Pharmaceuticals Statistics
Share Statistics
NovaBay Pharmaceuticals has 5.82M shares outstanding. The number of shares has increased by 438.09% in one year.
| Shares Outstanding | 5.82M |
| Shares Change (YoY) | 438.09% |
| Shares Change (QoQ) | 19.05% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 5.82M |
| Failed to Deliver (FTD) Shares | 415 |
| FTD / Avg. Volume | 0.57% |
Short Selling Information
The latest short interest is 32.7K, so 0.56% of the outstanding shares have been sold short.
| Short Interest | 32.7K |
| Short % of Shares Out | 0.56% |
| Short % of Float | 0.63% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.24 and the forward PE ratio is -1.51. NovaBay Pharmaceuticals's PEG ratio is 0.
| PE Ratio | -0.24 |
| Forward PE | -1.51 |
| PS Ratio | 0.21 |
| Forward PS | 0.2 |
| PB Ratio | -15.82 |
| P/FCF Ratio | -0.39 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for NovaBay Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.68, with a Debt / Equity ratio of -9.09.
| Current Ratio | 0.68 |
| Quick Ratio | 0.41 |
| Debt / Equity | -9.09 |
| Debt / EBITDA | -0.2 |
| Debt / FCF | -0.23 |
| Interest Coverage | -6.46 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $749.77K |
| Profits Per Employee | $-662.15K |
| Employee Count | 13 |
| Asset Turnover | 2.85 |
| Inventory Turnover | 4.27 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -78.52% in the last 52 weeks. The beta is 0.9, so NovaBay Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.9 |
| 52-Week Price Change | -78.52% |
| 50-Day Moving Average | 0.6 |
| 200-Day Moving Average | 0.71 |
| Relative Strength Index (RSI) | 48.44 |
| Average Volume (20 Days) | 72.34K |
Income Statement
In the last 12 months, NovaBay Pharmaceuticals had revenue of 9.75M and earned -8.61M in profits. Earnings per share was -2.53.
| Revenue | 9.75M |
| Gross Profit | 6.48M |
| Operating Income | -5.84M |
| Net Income | -8.61M |
| EBITDA | -5.92M |
| EBIT | -6.31M |
| Earnings Per Share (EPS) | -2.53 |
Balance Sheet
The company has 430K in cash and 1.17M in debt, giving a net cash position of -742K.
| Cash & Cash Equivalents | 430K |
| Total Debt | 1.17M |
| Net Cash | -742K |
| Retained Earnings | -183.46M |
| Total Assets | 3.42M |
| Working Capital | -908K |
Cash Flow
In the last 12 months, operating cash flow was -5.18M and capital expenditures -6K, giving a free cash flow of -5.19M.
| Operating Cash Flow | -5.18M |
| Capital Expenditures | -6K |
| Free Cash Flow | -5.19M |
| FCF Per Share | -1.53 |
Margins
Gross margin is 66.49%, with operating and profit margins of -59.91% and -88.31%.
| Gross Margin | 66.49% |
| Operating Margin | -59.91% |
| Pretax Margin | -88.31% |
| Profit Margin | -88.31% |
| EBITDA Margin | -60.79% |
| EBIT Margin | -59.91% |
| FCF Margin | -53.24% |
Dividends & Yields
NBY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for NBY is $0.85, which is 46.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $0.85 |
| Price Target Difference | 46.6% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on May 31, 2024. It was a backward split with a ratio of 1:35.
| Last Split Date | May 31, 2024 |
| Split Type | backward |
| Split Ratio | 1:35 |
Scores
| Altman Z-Score | -78.19 |
| Piotroski F-Score | 3 |